From the July 2020 issue of HealthCare Business News magazine
Each vendor offers its systems with several options to customize the configuration to best fit a hospital’s needs and budget. Hologic’s most popular systems are its high-end 3Dimensions and its low-end Selenia Dimensions 3D Performance. GE Healthcare offers the Senographe Pristina, Siemens Healthineers has its MAMMOMAT Revelation, and Fujifilm offers the Aspire Cristalle. Recent months’ data does not show an increase in lower-end systems or a decrease in highly configured systems. However, this will possibly change as hospitals obtain a better grasp on what they can budget for this technology post-pandemic.
According to MarketsandMarkets, the global mammography market was projected to grow from $3.7 billion to $5.4 billion between 2020 and 2025, due to increasing government investments in breast cancer detection and treatment, increased awareness by the general population, and a growing and aging population that is at risk for breast cancer. This projection may no longer be realistic, since the pandemic is currently having a global impact on healthcare systems and supply chains, and may impact future technological advancements.
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
As with all things impacted by COVID-19, the future of the mammography market is uncertain, and will largely depend on how long the pandemic continues and how severely it damages the economy. It is likely hospitals will have smaller budgets and may choose to keep currently installed systems for longer, opting out of newly available upgrades and keeping smaller fleets in operation, or they may consider purchasing refurbished systems over new. The behavior of hospitals after the pandemic could also limit market growth and technological breakthroughs. Vendors may shift more of their resources to developing other technologies if they receive too little revenue for mammography, slowing progress in women’s health. Continued observation and analysis will be needed to understand the long-term effects that the pandemic will have on the mammography market.
About the author: Kaitlyn Wilkie joined TractManager in 2017 as an analyst specializing in surgery. She currently focuses on women's health and ultrasound products. Ms. Wilkie received a Bachelor of Science degree in Animal Science from Texas A&M University and a Master of Business Administration degree from the University of North Texas at Dallas.Back to HCB News